Previous close | 55.55 |
Open | 54.45 |
Bid | 57.76 x 900 |
Ask | 60.04 x 1000 |
Day's range | 54.45 - 58.12 |
52-week range | 21.06 - 66.47 |
Volume | |
Avg. volume | 568,798 |
Market cap | 2.981B |
Beta (5Y monthly) | 0.50 |
PE ratio (TTM) | 39.29 |
EPS (TTM) | 1.47 |
Earnings date | 13 Feb 2023 - 17 Feb 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 84.60 |
DUBLIN, February 03, 2023--Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, January 31, 2023--Prothena announced positive topline Phase 1 SAD study results for PRX005, an investigational tau antibody for the treatment of Alzheimer’s disease.
DUBLIN, December 15, 2022--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it priced an underwritten public offering of 3,250,000 of its ordinary shares at a price to the public of $56.50 per ordinary share, before the underwriting discount and estimated offering expenses. All of the ordinary shares in the offering were sold by Prothena. In add